2023 Annual Meeting | C66 - Frontotemporal Dementia

Date Sunday 04/23/23

Time 03:30 PM - 05:30 PM EST Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Bradley F. Boeve, MD, FAAN

Topic(s) Aging, Dementia, and Behavioral Neurology

Learning Objectives Participants should become familiar with the key clinical, genetic, neuropsychological, and neuroimaging aspects of frontotemporal dementia, as well as the current and future management/treatment considerations for those with frontotemporal dementia.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Interpersonal and Communication Skills, Medical Knowledge, Practice-based Learning and Improvement, Systems-based Practice

Program Level Intermediate

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider

Teaching Styles Case-based, Didactic

Event Timeline
03:30 PM - 04:00 PM EST	Speaker	Clinical, Genetic, and Neuropsychological Aspects of FTD Bradley F. Boeve, MD, FAAN
04:00 PM - 04:30 PM EST	Speaker	Neuroimaging Aspects of FTD Howard J. Rosen, MD
04:30 PM - 05:00 PM EST	Speaker	Management/Treatment Aspects of FTD Peter A. Ljubenkov, MD
05:00 PM - 05:30 PM EST	Discussion	Open Discussion Bradley F. Boeve, MD, FAAN, Howard J. Rosen, MD, Peter A. Ljubenkov, MD

Faculty Disclosures
Bradley F. Boeve, MD, FAAN	Dr. Boeve has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Rainwater Charitable Foundation. The institution of Dr. Boeve has received research support from Alector. The institution of Dr. Boeve has received research support from EIP Pharma. The institution of Dr. Boeve has received research support from Transposon. The institution of Dr. Boeve has received research support from Cognition Therapeutics. Dr. Boeve has received publishing royalties from a publication relating to health care.
Howard J. Rosen, MD	Dr. Rosen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai Pharmaceuticals. Dr. Rosen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. The institution of Dr. Rosen has received research support from NIH. The institution of Dr. Rosen has received research support from State of CA. Dr. Rosen has a non-compensated relationship as a Consultant with Alector that is relevant to AAN interests or activities. Dr. Rosen has a non-compensated relationship as a Consultant with Prevail Therapeutics that is relevant to AAN interests or activities. Dr. Rosen has a non-compensated relationship as a consultant with Alchemab that is relevant to AAN interests or activities.
Peter A. Ljubenkov, MD	Dr. Ljubenkov has nothing to disclose.